Welcome to our dedicated page for Janux Therapeutics SEC filings (Ticker: JANX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Janux Therapeutics filings document a clinical-stage biopharmaceutical issuer developing tumor-activated immunotherapies through the TRACTr, TRACIr and ARM platforms. Recent 8-K reports furnish financial results and business updates covering clinical programs such as JANX007, JANX014, JANX011 and JANX008, as well as cash-position commentary and pipeline prioritization.
The company’s regulatory record also includes a material definitive agreement for the Bristol Myers Squibb collaboration, with license, development, commercialization, milestone and royalty terms. Proxy and governance filings document director elections, board-classification matters, executive compensation, pay-versus-performance disclosure and officer or director changes.
Janux Therapeutics, Inc. is reported to have 1,993,837 shares of its common stock beneficially owned through investment funds managed by Point72 Asset Management, L.P. and related entities, representing 3.3% of the outstanding class as of June 30, 2026. Voting and dispositive power over these shares is reported on a shared basis among Point72 Asset Management, Point72 Capital Advisors, Inc., and Steven A. Cohen, each of whom disclaims beneficial ownership for certain legal purposes.
Janus Henderson Group Ltd. reports beneficial ownership of common stock of Janux Therapeutics, Inc. as a parent of multiple affiliated asset managers. The group is deemed to beneficially own 172,229 shares of Janux Therapeutics common stock, representing 0.3% of the class.
The shares are held across various client accounts of Janus Henderson’s investment adviser subsidiaries (the “Managed Portfolios”). Janus Henderson and its asset managers have shared voting and dispositive power over 172,229 shares and no sole voting or dispositive power. The Managed Portfolios, rather than Janus Henderson, have the right to receive all dividends and sale proceeds from these securities, and no individual Managed Portfolio holds more than five percent of Janux Therapeutics’ common stock.
Janux Therapeutics, Inc. reported Q2 2026 results highlighted by collaboration revenue of approximately $10.3 million from its Bristol-Myers Squibb agreement and a net loss of about $22.0 million, compared with a $33.9 million net loss a year earlier.
For the first half of 2026, collaboration revenue was $14.0 million and the net loss was $46.3 million. Operating expenses were about $42.0 million in the quarter, mainly for research and development and general and administrative activities, while interest income contributed $9.7 million.
Janux ended June 30, 2026 with $27.8 million in cash and cash equivalents, $943.1 million in short-term investments, and total assets of roughly $1.01 billion. The company is advancing multiple clinical programs, including PSMA-targeted TRACTr and TRACIr candidates and its CD19-ARM program for autoimmune diseases. Management believes existing capital will fund operations for at least 12 months while it continues to incur substantial research and development spending and operating losses.
Janux Therapeutics, Inc. reported results for the quarter ended June 30, 2026 and provided a clinical update. The company is advancing multiple programs, including JANX007 and JANX014 in metastatic castration-resistant prostate cancer, JANX011 in a Phase 1 healthy volunteer trial, and expects to initiate JANX013 in the second half of 2026.
Collaboration revenue was $10.267 million in the quarter, with a net loss of $21.972 million, compared with a net loss of $33.858 million a year earlier, or $0.35 per share versus $0.55. Cash, cash equivalents and short-term investments totaled $970.9 million as of June 30, 2026, slightly above $966.6 million at December 31, 2025, supporting continued development across the TRACTr, TRACIr and ARM platforms.
Janux Therapeutics, Inc. director and President and CEO David Alan Campbell reported a bona fide gift of 123840.0000 shares of Common Stock on July 31, 2026. The transfer was recorded at $0.0000 per share, and he now directly holds 264742.0000 shares following the transaction.
BlackRock, Inc. filed an amended Schedule 13G reporting its beneficial ownership of common stock of Janux Therapeutics, Inc. As of June 30, 2026, BlackRock reported beneficial ownership of 4,098,457 shares of Janux common stock, representing 6.7% of the outstanding class.
BlackRock reported sole voting power over 4,024,396 shares and sole dispositive power over 4,098,457 shares, with no shared voting or dispositive power. Various underlying clients have rights to dividends or sale proceeds, but no individual client holds more than five percent of Janux’s outstanding common shares.
Janux Therapeutics, Inc. President and CEO David Alan Campbell exercised stock options to acquire 7,000 shares of common stock at an exercise price of $4.21 per share. Following the transaction on July 8, 2026, he holds 388,582 common shares directly and 697,550 stock options remaining, with the exercised option series immediately exercisable and expiring on March 9, 2031.
Janux Therapeutics, Inc. reported that its Chief Medical Officer, William Go, M.D., Ph.D., departed the company on June 23, 2026. The departure was treated as a termination without “Cause” under Janux’s Change in Control and Severance Benefit Plan.
The company has begun searching for a new Chief Medical Officer. Until a successor is appointed, existing clinical leaders will collectively handle the responsibilities. Janux stated that this transition does not change its development strategy, regulatory plans, or previously disclosed clinical timelines, and that Dr. Go’s departure did not stem from any disagreement over operations, policies, or practices.
Janux Therapeutics, Inc. reported insider-related equity awards linked to RA Capital–associated entities. An arrangement for Dr. Jake Simson includes a grant of 5,500 restricted stock units (RSUs), each representing one share of common stock, and 15,500 stock options with a $13.66 exercise price. The RSUs vest on the earlier of June 11, 2027 or the next annual stockholder meeting, subject to Dr. Simson’s continuous service, while the options vest in equal monthly installments over the 12 months following June 11, 2026 and in any case by the next annual meeting. Dr. Simson holds these awards for the benefit of RA Capital funds, must deliver any net shares or cash to the adviser to offset advisory fees, and the reporting persons disclaim beneficial ownership except for any pecuniary interest.
Janux Therapeutics director Jake Simson reported equity awards tied to his board service. He received 5,500 restricted stock units, each representing one share of common stock, vesting on the earlier of June 11, 2027 or the next annual stockholder meeting, subject to continuous service. He was also granted options for 15,500 shares at an exercise price of $13.66 per share, vesting in equal monthly installments over the 12 months following June 11, 2026 and fully vested by the next annual meeting, subject to continued service. After these awards, his reported direct common stock holdings total 11,750 shares. Under an arrangement with RA Capital Management, these RSUs and options are held for the benefit of RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund II, L.P., and Simson is obligated to turn over any net stock or cash received, so he disclaims beneficial ownership.